Short-Term Calorie Reduction Benefits DLBCL Patients

By Robert Dillard - Last Updated: October 1, 2021

Short-term calorie reduction (SCR) may benefit patients with diffuse large B-cell lymphoma (DLBCL) according to a study published in Nutrients.

“SCR requires individuals to reduce their calorie intake to less than 50% of normal requirements and has shown good tolerance and potential benefits in prior studies addressing gynecological cancer patients. More studies are needed to further confirm its safety, feasibility, and effects in patients with different cancers, including hematological malignancies,” the researchers wrote.

To conduct this study, patients with advanced-stage DLBCL underwent SCR group and were matched with 1:1 to comparison patients in double-blinded fashion. The SCR group underwent at least two cycles of 48-hour water fasting along with chemotherapy (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone). The researchers used descriptive analysis and generalized estimating equations to assess the data. Overall, six participants completed multiple cycles of SCR and were compared to six counterparts.

The results showed that SCR is safe and feasible in terms of a high compliance rate and stable nutritional status. “The SCR was associated with benefits in post-chemotherapy hematological parameters (i.e., erythrocyte [P <0.001] and lymphocyte counts [P<0.001]). More randomized controlled trials are needed to validate the effects of SCR on different types of cancer populations,” the researchers concluded.

Post Tags:DLBCL